Management appointments at Seattle Genetics
This article was originally published in Scrip
Executive Summary
Seattle Genetics has appointed Natasha Hernday vice-president of corporate development. Ms Hernday, who has 10 years' experience in business and corporate development, joins from Amgen, where she held roles of increasing responsibility in research, research project management and business development finance, before joining the corporate development group in 2000. Seattle has also promoted Dr Eric Sievers to vice-president of clinical affairs. He joined the company in 2006, most recently serving as executive medical director, and has played a leadership role in the company's brentuximab vedotin (SGN-35) programme, including the recent BLA submission to the US FDA.